Find Clinical Trials

All CategoriesMedications / Interventions»Aa»Alemtuzumab



Join Paid Clinical Trials



  • Condition:   Allogeneic Hematopoietic Cell Transplantation
    Intervention:   Drug: Alemtuzumab
    Sponsor:   Children's Hospital Medical Center, Cincinnati
    Recruiting

  • Condition:   Multiple Sclerosis (MS)
    Intervention:   Drug: Alemtuzumab
    Sponsors:   University of Texas Southwestern Medical Center;   Genzyme, a Sanofi Company
    Recruiting

  • Condition:   Multiple Sclerosis
    Intervention:   Drug: Alemtuzumab (GZ402673)
    Sponsor:   Genzyme, a Sanofi Company
    Recruiting

  • Conditions:   T-Cell Lymphoma Relapsed;   Adult T-Cell Leukemia (ATL);   Peripheral T-Cell Lymphoma (PTCL);   Cutaneous T Cell Lymphoma (CTCL);   T-Cell Prolymphocytic Leukemia
    Intervention:   Biological: IL-15 plus alemtuzumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Multiple Sclerosis
    Intervention:   Other: Assessment of leukocyte function.
    Sponsor:   University of Southern California
    Recruiting

  • Condition:   Sickle Cell Disease
    Intervention:   Drug: Alemtuzumab intravenously, low dose total body irradiation, Sirolimus
    Sponsors:   Allistair Abraham, MD;   Alberta Children's Hospital;   The Hospital for Sick Children;   Levine Children's Hospital
    Recruiting

  • Condition:   Chronic Granulomatous Disease
    Interventions:   Drug: Busulfan;   Drug: Alemtuzumab;   Drug: Cyclophosphamide;   Drug: Sirolimus;   Radiation: Total Body Irradiation;   Biological: Allogeneic peripheral blood stem cell
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Not yet recruiting

  • Condition:   Sickle Cell Disease
    Interventions:   Drug: Alemtuzumab;   Radiation: Total Body Irradiation;   Drug: Sirolimus
    Sponsor:   Kathleen Dorritie
    Recruiting

  • Condition:   Kidney Transplantation
    Intervention:   Drug: Belimumab
    Sponsors:   University of Wisconsin, Madison;   GlaxoSmithKline;   American College of Surgeons
    Recruiting

  • Conditions:   Immune Deficiency Disorders;   Severe Combined Immunodeficiency;   Chronic Granulomatous Disease;   X-linked Agammaglobulinemia;   Wiskott-Aldrich Syndrome;   Hyper-IgM;   DiGeorge Syndrome;   Chediak-Higashi Syndrome;   Common Variable Immune Deficiency;   Immune Dysregulatory Disorders;   Hemophagocytic Lymphohistiocytosis;   IPEX;   Autoimmune Lymphoproliferative Syndrome;   X-linked Lymphoproliferative Syndrome
    Intervention:   Drug: Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
    Sponsor:   Washington University School of Medicine
    Recruiting

  • Conditions:   Non Malignant Diseases;   Immunodeficiencies;   Hemoglobinopathies
    Interventions:   Drug: RIC: Distal Campath;   Drug: RIC:Intermediate Campath;   Drug: RIC: Mini Busulfan
    Sponsor:   Children's Hospital of Philadelphia
    Recruiting

  • Conditions:   Acute Myeloid Leukemia (AML);   Myelodysplastic Syndrome (MDS);   Hematopoietic Stem Cell Transplant (HSCT)
    Interventions:   Drug: Reduced-Intensity Conditioning Regimen;   Drug: Myeloablative Conditioning Regimen
    Sponsor:   Randy Windreich
    Recruiting

  • Conditions:   Sickle Cell Disease;   Beta Thalassemia
    Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: Alemtuzumab;   Procedure: Allogeneic stem cell transplant
    Sponsor:   Columbia University
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Non Hodgkins Lymphoma;   Myelodysplastic Syndrome;   Acute Myeloid Leukemia;   Chronic Myelogenous Leukemia;   Hemophagocytic Lymphohistiocytosis (HLH);   Familial Hemophagocytic Lymphohistiocytosis (FLH);   Viral-associated Hemophagocytic Syndrome (VAHS);   X-linked Lymphoproliferative Disease (XLP)
    Interventions:   Drug: Ara-C;   Drug: Cyclophosphamide;   Biological: Campath-1H;   Radiation: Total Body Irradiation;   Procedure: Stem Cell Infusion
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   Texas Children's Hospital;   The Methodist Hospital System
    Recruiting

  • Conditions:   Primary Immunodeficiency (PID);   Congenital Bone Marrow Failure Syndromes;   Inherited Metabolic Disorders (IMD);   Hereditary Anemias;   Inflammatory Conditions
    Interventions:   Drug: Hydroxyurea;   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Thiotepa
    Sponsor:   Paul Szabolcs
    Recruiting

  • Conditions:   Kidney Transplantation;   Renal Transplantation;   Renal Transplant Recipient
    Interventions:   Biological: Donor-derived Mesenchymal Stromal Cells;   Drug: alemtuzumab;   Drug: belatacept;   Drug: sirolimus;   Drug: mycophenolate mofetil;   Drug: mycophenolate acid;   Drug: prednisone
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Immune Tolerance Network (ITN)
    Recruiting

  • Conditions:   Congenital Hemolytic Anemia;   Sickle Cell Disease
    Interventions:   Procedure: Peripheral blood hematopoietic progenitor cell (PBPC) transplant;   Drug: Alemtuzumab;   Procedure: Peripheral blood hematopoieticprogenitor cell Apherisis;   Drug: Sirolimus
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Condition:   Sickle Cell Disease
    Interventions:   Drug: Alemtuzumab;   Drug: Cyclophosphamide;   Drug: Mycophenolate mofetil;   Drug: Sirolimus;   Drug: Fludarabine;   Radiation: Total body irradiation;   Procedure: Hematopoietic stem cell transplant
    Sponsor:   Washington University School of Medicine
    Recruiting

  • Conditions:   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma
    Interventions:   Drug: Bendamustine;   Drug: Carmustine;   Drug: Etoposide;   Drug: Melphalan;   Drug: Cytarabine;   Drug: Alemtuzumab;   Biological: Autologous Stem Cell Transplantation;   Biological: Allogeneic Stem Cell Transplantation;   Drug: Rituximab
    Sponsor:   Weill Medical College of Cornell University
    Recruiting

  • Conditions:   Chronic Myeloid Leukemia (CML);   Acute Myelogenous Leukemia (AML);   Myelodysplastic Syndrome (MDS);   Juvenile Myelomonocytic Leukemia (JMML);   Acute Lymphoblastic Leukemia (ALL);   Lymphoma (Hodgkin's and Non-Hodgkin's)
    Interventions:   Device: CliniMACS CD34+ Reagent System;   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Alemtuzumab;   Drug: Tacrolimus;   Drug: Melphalan;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Methylprednisolone
    Sponsor:   Diane George, MD
    Recruiting

  • Conditions:   Sickle Cell Disease;   Thalassemia;   Stem Cell Transplantation;   Graft vs Host Disease
    Interventions:   Drug: Alemtuzumab;   Drug: Sirolimus;   Drug: Cyclophosphamide;   Drug: Pentostatin;   Procedure: Radiotherapy
    Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   National Institutes of Health Clinical Center (CC)
    Recruiting

  • Conditions:   Leukemia, Erythroblastic, Acute;   Myelodysplastic Syndromes
    Interventions:   Drug: 5-Azacytidine;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Alemtuzumab;   Radiation: Total Body Irradiation
    Sponsor:   Weill Medical College of Cornell University
    Recruiting

  • Conditions:   Dyskeratosis Congenita;   Aplastic Anemia
    Interventions:   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Biological: Stem Cell Transplant;   Drug: Anti-thymocyte globulin
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   SCID;   Omenn's Syndrome;   Reticular Dysgenesis;   Wiskott-Aldrich Syndrome;   Bare Lymphocyte Syndrome;   Common Variable Immunodeficiency;   Chronic Granulomatous Disease;   CD40 Ligand Deficiency;   Hyper IgM Syndrome;   X-linked Lymphoproliferative Disease;   Hemophagocytic Lymphohistiocytosis;   Griscelli Syndrome;   Chediak-Higashi Syndrome;   Langerhan's Cell Histiocytosis
    Interventions:   Drug: Alemtuzumab 0.3 mg;   Drug: Cyclophosphamide;   Drug: Busulfan;   Biological: Stem Cell Transplantation;   Drug: Fludarabine phosphate 40 mg;   Drug: Melphalan;   Drug: Alemtuzumab 0.2 mg;   Drug: Fludarabine phosphate 30 mg;   Drug: MESNA
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Inherited Immune Deficiencies
    Interventions:   Drug: Fludarabine;   Drug: Total Body Irradiation, Busulfan, Campath-1H, or h-ATG, Fludarabine;   Drug: Sirolimus or equivalent based on response;   Drug: Granulocyte Colony Stimulating Factor (G-CSF);   Other: hematopoietic progenitor cells
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  • Conditions:   Sickle Cell Anemia;   Beta-thalassemia Major;   Diamond-blackfan Anemia
    Interventions:   Biological: CD3/CD19 depleted leukocytes;   Biological: CD45RA depleted leukocytes;   Drug: Hydroxyurea;   Drug: Rituximab;   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Thiotepa
    Sponsor:   Beth Carella, DO
    Recruiting

  • Conditions:   Idiopathic Pulmonary Fibrosis;   Emphysema or COPD
    Interventions:   Biological: CD3/CD19 negative hematopoietic stem cells;   Drug: Rituximab;   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Thiotepa;   Drug: G-CSF;   Drug: Hydroxyurea
    Sponsor:   Paul Szabolcs
    Recruiting

  • Conditions:   Systemic Sclerosis;   Diffuse Sclerosis Systemic;   Interstitial Lung Disease;   Pulmonary Hypertension
    Interventions:   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Rituximab;   Drug: Alemtuzumab;   Drug: Thiotepa;   Drug: GM-CSF;   Drug: Intravenous immunoglobulin;   Radiation: Total Body Irradiation
    Sponsor:   Paul Szabolcs
    Recruiting

  • Condition:   Sickle Cell Disease and Thalassemia
    Intervention:   Biological: Donor Stem Cell Transplantation
    Sponsor:   University of Texas Southwestern Medical Center
    Recruiting

  • Conditions:   Dyskeratosis Congenita;   Hoyeraal Hreidarsson Syndrome;   Revesz Syndrome;   Aplastic Anemia
    Interventions:   Biological: alemtuzumab;   Drug: Fludarabine;   Drug: Cyclosporins;   Drug: Mycophenolate mofetil
    Sponsors:   Boston Children’s Hospital;   Dana-Farber Cancer Institute;   Children's Hospital Medical Center, Cincinnati;   Children's Hospital Los Angeles;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   Baylor College of Medicine;   Children's Hospital of Philadelphia;   Memorial Sloan Kettering Cancer Center;   University of Wisconsin, Madison;   Karolinska University Hospital
    Recruiting

  • Condition:   Multiple Sclerosis, Relapsing-Remitting
    Interventions:   Drug: Early Highly Effective Therapies Group;   Drug: Escalation Therapies Group
    Sponsors:   The Cleveland Clinic;   University of Nottingham
    Recruiting

  • Conditions:   Metabolic Disorders;   Hematologic, Immune, or Bone Marrow Disorders;   Hemoglobinopathies;   Non-malignant Disorders
    Interventions:   Drug: Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan;   Drug: Transplant conditioning regimen of hydroxyurea, campath, fludarabine, thiotepa, & melphalan
    Sponsors:   Washington University School of Medicine;   St. Louis Children's Hospital
    Recruiting

  • Condition:   X-Linked Chronic Granulomatious Disease
    Interventions:   Drug: Campath;   Drug: Busulfan;   Other: allogeneic peripheral blood allograft infusion;   Drug: cyclophosphamide
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  • Condition:   Crohn's Disease
    Interventions:   Biological: autologous CD34-selected peripheral blood stem cells transplant;   Drug: Alemtuzumab;   Drug: ATG;   Drug: Melphalan;   Drug: Thiotepa;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: G-CSF;   Drug: Mesna
    Sponsor:   Paul Szabolcs
    Recruiting

  • Conditions:   Bone Marrow Failure Syndrome;   Severe Aplastic Anemia;   Severe Congenital Neutropenia;   Amegakaryocytic Thrombocytopenia;   Diamond-Blackfan Anemia;   Schwachman Diamond Syndrome;   Primary Immunodeficiency Syndromes;   Acquired Immunodeficiency Syndromes;   Histiocytic Syndrome;   Familial Hemophagocytic Lymphocytosis;   Lymphohistiocytosis;   Macrophage Activation Syndrome;   Langerhans Cell Histiocytosis (LCH);   Hemoglobinopathies;   Sickle Cell Disease;   Sickle Cell-beta-thalassemia
    Intervention:   Biological: CD34 Stem Cell Selection Therapy
    Sponsor:   Diane George, MD
    Recruiting

  • Conditions:   Facial Injuries;   Traumatic Wounds and Injuries;   Craniofacial Injuries;   Craniofacial Defects
    Intervention:   Drug: Bone marrow cell-based therapy & 1-drug immunosuppression.
    Sponsor:   Johns Hopkins University
    Recruiting

  • Conditions:   Severe Sickle Cell Disease;   Bone Marrow Failure Syndromes;   Metabolic Disorders;   Immunologic Disorders;   Hemoglobinopathies;   Non-malignant Disorders
    Interventions:   Drug: RIC regimen;   Drug: GVHD prophylaxis regimen
    Sponsor:   Washington University School of Medicine
    Recruiting

  • Conditions:   Sickle Cell Disease;   Transfusion Dependent Alpha- or Beta- Thalassemia;   Diamond Blackfan Anemia;   Paroxysmal Nocturnal Hemoglobinuria;   Glanzmann Thrombasthenia;   Severe Congenital Neutropenia;   Shwachman-Diamond Syndrome;   Non-Malignant Hematologic Disorders
    Interventions:   Drug: Reduced Toxicity Ablative Regimen;   Drug: Reduced Intensity Preparative Regimen;   Drug: Myeloablative Preparative Regimen
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Amputation, Traumatic;   Wounds and Injuries;   Hand Injuries
    Interventions:   Procedure: Deceased donor hand transplantation;   Drug: Bone marrow cell-based therapy & single-drug immunosuppression.
    Sponsors:   Johns Hopkins University;   Armed Forces Institute of Regenerative Medicine;   U.S. Army Medical Research Acquisition Activity
    Recruiting

  • Conditions:   Sickle Cell Disease;   Graft Versus Host Disease
    Interventions:   Drug: Diphenhydramine;   Drug: Acetaminophen;   Drug: Methylprednisolone;   Drug: Meperidine;   Drug: Alemtuzumab;   Drug: Thymoglobulin;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Thiotepa;   Drug: Cyclosporine;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: Abatacept;   Procedure: Marrow infusion;   Drug: Sirolimus;   Drug: Mycophenolate Mofetil
    Sponsor:   Monica Bhatia
    Recruiting

  • Condition:   Multiple Sclerosis, Relapsing-Remitting
    Intervention:   Other: Early Aggressive Therapy or Traditional Therapy
    Sponsors:   Johns Hopkins University;   Patient-Centered Outcomes Research Institute
    Recruiting

  • Conditions:   Mucopolysaccharidosis Disorders;   Hurler Syndrome;   Hunter Syndrome;   Maroteaux Lamy Syndrome;   Sly Syndrome;   Alpha-Mannosidosis;   Fucosidosis;   Aspartylglucosaminuria;   Glycoprotein Metabolic Disorders;   Sphingolipidoses;   Recessive Leukodystrophies;   Globoid Cell Leukodystrophy;   Metachromatic Leukodystrophy;   Niemann-Pick B;   Niemann-Pick C Subtype 2;   Sphingomyelin Deficiency;   Peroxisomal Disorders;   Adrenoleukodystrophy With Cerebral Involvement;   Zellweger Syndrome;   Neonatal Adrenoleukodystrophy;   Infantile Refsum Disease;   Acyl-CoA Oxidase Deficiency;   D-Bifunctional Enzyme Deficiency;   Multifunctional Enzyme Deficiency;   Alpha-methylacyl-CoA Racmase Deficiency;   Mitochondrial Neurogastrointestingal Encephalopathy;   Severe Osteopetrosis;   Hereditary Leukoencephalopathy With Axonal Spheroids (HDLS; CSF1R Mutation);   Inherited Metabolic Disorders
    Interventions:   Biological: Stem Cell Transplantation;   Drug: IMD Preparative Regimen;   Drug: Osteopetrosis Only Preparative Regimen;   Drug: Osteopetrosis Haploidentical Only Preparative Regimen;   Drug: cALD SR-A (Standard-Risk, Regimen A);   Drug: cALD SR-B (Standard-Risk, Regimen B);   Drug: cALD HR-D (High-Risk, Regimen C);   Drug: cALD HR-D (High-Risk, Regimen D)
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

Login to Get Started